{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:51:34Z","timestamp":1786992694695,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jinf.2021.07.030","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T04:16:07Z","timestamp":1627445767000},"page":"490-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of treatment duration on recurrence of chronic pulmonary aspergillosis"],"prefix":"10.1016","volume":"83","author":[{"given":"Yunjoo","family":"Im","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woo","family":"Jhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jung","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongman","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2021.07.030_bib0001","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1183\/09031936.00054810","article-title":"Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma","volume":"37","author":"Smith","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2021.07.030_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01184-2018","article-title":"Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation","volume":"53","author":"Page","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2021.07.030_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00117-2019","article-title":"Nontuberculous mycobacterial pulmonary disease and aspergillus co-infection: bonnie and clyde?","volume":"54","author":"Geurts","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2021.07.030_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2021.07.030_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2021.07.030_bib0006","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1080\/13693780500064771","article-title":"The radiological spectrum of pulmonary aspergillosis","volume":"43","author":"Greene","year":"2005","journal-title":"Med Mycol"},{"key":"10.1016\/j.jinf.2021.07.030_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03345-2020","article-title":"Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis","author":"Maitre","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2021.07.030_bib0008","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"key":"10.1016\/j.jinf.2021.07.030_bib0009","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10096-012-1690-y","article-title":"Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial","volume":"31","author":"Cadranel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.jinf.2021.07.030_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jiac.2014.02.003","article-title":"Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles","volume":"20","author":"Koyama","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jinf.2021.07.030_bib0011","article-title":"Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy","volume":"5","author":"Bongomin","year":"2020","journal-title":"Clin Infect Pract"},{"key":"10.1016\/j.jinf.2021.07.030_bib0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.07.030_bib0013","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2021.07.030_bib0014","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jac\/dkx390","article-title":"A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention","volume":"73","author":"Godet","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2021.07.030_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000489474","article-title":"Treatment of chronic pulmonary aspergillosis: current standards and future perspectives","volume":"96","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.jinf.2021.07.030_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2020.101041","article-title":"Clinical features and outcome of patients with chronic pulmonary aspergillosis in China: a retrospective, observational study","volume":"30","author":"Niu","year":"2020","journal-title":"J Mycol Med"},{"key":"10.1016\/j.jinf.2021.07.030_bib0017","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/cid\/ciz287","article-title":"Selection of oral antifungals for initial maintenance therapy in chronic pulmonary aspergillosis: a longitudinal analyze","volume":"70","author":"Tashiro","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.07.030_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249455","article-title":"Prognostic factors of chronic pulmonary aspergillosis: a retrospective cohort of 264 patients from Japan","volume":"16","author":"Kimura","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jinf.2021.07.030_bib0019","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jinf.2014.01.005","article-title":"Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis","volume":"68","author":"Shin","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2021.07.030_bib0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/13693786.2013.806826","article-title":"Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis","volume":"51","author":"Jhun","year":"2013","journal-title":"Med Mycol"},{"key":"10.1016\/j.jinf.2021.07.030_bib0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jinf.2021.07.030_bib0022","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","article-title":"Efficacy and safety of posaconazole for chronic pulmonary aspergillosis","volume":"51","author":"Denning","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.07.030_bib0023","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1378\/chest.06-2441","article-title":"Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients","volume":"131","author":"Camuset","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2021.07.030_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/jof6030096","article-title":"CPAnet registry-an international chronic pulmonary aspergillosis registry","volume":"6","author":"Laursen","year":"2020","journal-title":"J Fungi"},{"key":"10.1016\/j.jinf.2021.07.030_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193732","article-title":"Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis","volume":"13","author":"Bongomin","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jinf.2021.07.030_bib0026","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/cid\/cit411","article-title":"Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis","volume":"57","author":"Al-shair","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2021.07.030_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.02.640","article-title":"CT Imaging assessment of response to treatment in chronic pulmonary aspergillosis","volume":"150","author":"Godet","year":"2016","journal-title":"Chest"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321003716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321003716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:33:39Z","timestamp":1759008819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445321003716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0163445321003716"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2021.07.030","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of treatment duration on recurrence of chronic pulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2021.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}